Valeant Announces Third-Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharma (VRX) Trades Near High, Up 18%
November 7, 2017 9:44 AM ESTValeant Pharma (NYSE: VRX) Trades Near High, Up 18%
... MoreValeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views
November 7, 2017 7:10 AM ESTValeant Pharma (NYSE: VRX) reported Q3 GAAP EPS of $3.69, versus ($3.49) last year. Revenue for the quarter came in at $2.22 billion, versus $2.48 billion reported last year and the consensus of $2.165 billion. Adjusted EBITDA (non-GAAP) of $951 million, versus the consensus of $872 million and adjusted Net Income of $367 million versus the consensus of $311 million.
"Our strong third-quarter performance... More
